Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR-tyrosine kinase inhibitors

BACKGROUND: Multiple prospective studies have demonstrated that epidermal growth factor receptor (EGFR) exon 19 and exon 21 mutations are the most powerful predictive biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small-cell lung cancer (NSCLC). However, there are f...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Thorac Cancer
Main Authors: Wei, Zhigang, An, Tongtong, Wang, Zhijie, Chen, Keneng, Bai, Hua, Zhu, Guangying, Duan, Jianchun, Wu, Meina, Yang, Lu, Zhuo, Minglei, Wang, Yuyan, Liu, Xuyi, Wang, Jie
פורמט: Artigo
שפה:Inglês
יצא לאור: BlackWell Publishing Ltd 2014
נושאים:
Original Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4704323/
https://ncbi.nlm.nih.gov/pubmed/26766989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12068
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים